Associate Professor Somshuvra Mukhopadhyay, M.B.B.S., Ph.D. wins the 2020 Co-op Research Excellence Award for Best Paper. The awards are presented each year by the Office of the Vice President for Research and the University Co-operative Society.
Join Assistant Dean of Diversity and Inclusion Skyller Walkes, Ph.D. and Russell Boyd II on Wednesday, September 16 at 5 p.m. CT for an online discussion about the power of your vote. Boyd is an activist, organizer, and currently serves as the National Field Organizer with the NAACP Youth & College Division.
P4 students in each of the college’s five experiential regions chose a local Preceptor of the Year for 2020 based on their rotations during the 2019-20 academic year. Past recipients of the Wm. Arlyn Kloesel Preceptor of the Year award declared Kristin Janzen, Pharm.D. this year’s winner.
Practicing pharmacists: Complete your continuing pharmacy education hours virtually with UT’s Pharmacy Practice Seminar (PPS), September 26-27, 2020. UT’s PPS is developed by pharmacists, for pharmacists. Pick from over 25 CE hours that actually benefit your practice. Go to the UT PPS website to register.
Associate Dean for Research and Graduate Studies John H. Richburg, Ph.D. received notice from the National Institutes of Health (NIH) awarding him a research grant for a five-year term. The NIH’s grant award for Dr. Richburg’s research totals $2,694,316.
The University of Texas at Austin has named Dr. Samuel Poloyac the next dean of the College of Pharmacy. He will begin serving October 15. Poloyac is a professor of pharmaceutical sciences and the associate dean for graduate and postdoctoral programs at the University of Pittsburgh School of Pharmacy. He will succeed M. Lynn Crismon, who served as dean for 13 years of distinguished leadership in the college.
Dean M. Lynn Crismon addresses a recent social media post featuring a letter from 1951 denying admission of an African-American applicant to The University of Texas College of Pharmacy based upon the color of the person’s skin.
Researchers in the Division of Molecular Pharmaceutics and Drug Delivery, led by Robert O. (Bill) Williams III, plan to use their novel thin-film-freezing technology to deliver remdesivir through dry powder inhalation, potentially making COVID-19 antiviral treatment more potent, easier to administer, and more broadly available.
